Impact of COVID-19 Omicron variant on lung transplantation patients with 1-year follow-up: A single tertiary medical center experience.

Background: Lung transplantation patients with coronavirus disease 2019 (COVID-19) have high mortality. However, the impact of the Omicron variant in lung transplantation patients is unclear. This study focuses on lung transplant patients diagnosed with COVID-19 during the Omicron wave, and investigate the clinical presentations, outcomes and pulmonary function.

Methods: In this single-center retrospective study, we enrolled lung transplantation patients diagnosed with COVID-19 from January 2022 to December 2022. Demographic, laboratory and pulmonary function data were recorded. Pre-COVID-19 pulmonary function data were obtained from the closest routine test, and post-COVID-19 tests were arranged after release from isolation.

Results: Of the 22 enrolled patients, four were admitted to general wards for treatment and observation, and two needed oxygen support. All of the patients recovered from COVID-19. There were no significant decreases in forced vital capacity (FVC) (2.3 ± 0.6 vs. 2.2 ± 0.8 L, p = 0.363) and forced expiratory volume in the first second (FEV1) (2.0 ± 0.6 vs. 1.9 ± 0.8 L, p = 0.269) after COVID-19 infection. Daily prednisolone dose and serum tacrolimus levels were significantly correlated to the duration of positive COVID-19 test and change in FEV1. Patients who did not receive a booster dose of COVID-19 vaccination had a significantly longer positive test duration (9.1 ± 4.1 vs. 26.6 ± 24.4 days, p = 0.05), and greater decrease in FEV1 (23.6 ± 137.3 vs. -331.8 ± 537.8 L, p = 0.040).

Conclusions: In this study, lung transplant patients infected with COVID-19 during the Omicron wave had low rate of severe disease and mortality. Immunosuppressive medications and COVID-19 vaccination were correlated with viral clearance and pulmonary function after COVID-19 infection.